Epilepsy Market Growing Opportunity, Demand, Market Size, Share and Growth
Posted by Rohit Kamble on March 23rd, 2020
Epilepsy Market Research Report: by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), by Diagnosis & Treatment (Diagnosis & Treatment), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), and Region - Forecast till 2023
The Epilepsy Market In-Depth competition analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue.
Major Key Players
The key strategies followed by the players operating in the global Epilepsy Market were innovation, product development, acquisition, and expansion.
LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), and Abbott Laboratories (U.S.).
Market Segment Analysis
The global epilepsy market is segmented by condition, diagnosis & treatment, and end-user.
By condition, the ‘others’ segment accounted for 70.5% market share in 2017. It is touted to reach a worth close to USD 6,571.40 million by 2023. On the other hand, the drug resistant epilepsy segment is projected to reach a valuation of USD 2,937.80 million by the end of the forecast period. Emergence of rational polytherapy for treating the disorder with negligible side-effects is likely to accrue significant revenue for the epilepsy market.
By diagnosis & treatment, the treatment segment held 66.2% share of the epilepsy market in 2017. The segment can exhibit 7.91% CAGR during the forecast period due to availability of affordable drugs for treating partial epileptic seizures. In addition, approval of effective drugs by regulatory agencies can facilitate growth in the segment. It is expected to be worth USD 6,198.63 million by 2023. On the other hand, the diagnosis segment is predicted to enjoy 8.76% CAGR over the assessment period. Utilization of various imaging tests and blood tests for early discernment of the disorder is expected to drive the segment growth exponentially. For instance, CT scans are used for revealing abnormalities in the brain which can catch the probability of epilepsy at an early stage.
By end-user, hospitals were the largest segment of the market with a valuation of USD 1,739.22 million in 2017. It is projected to exhibit a stellar 8.29% CAGR over the forecast period. On the other hand, clinics can showcase higher CAGR of 8.93% during the assessment period owing to clinics being a preferred center for diagnosis and
Key Study Highlights:
Geographically, the global Epilepsy Market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa
Browse Full Report Page Enabled with complete Table of Content https://www.marketresearchfuture.com/reports/epilepsy-market-7730
Chapter 9. Global Epilepsy Market By Region
9.2.1 North America
9.2.2 South America
9.3.1 Western Europe
220.127.116.11 Rest Of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.5 Republic Of Korea
9.4.6 Rest Of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.6 Rest Of The Middle East & Africa
About Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
+1 646 845 9312 | Email: email@example.com
Like it? Share it!
About the AuthorRohit Kamble
Joined: February 25th, 2019
Articles Posted: 194
More by this author